Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study
Centre Hospitalier Universitaire de Nantes · Kyiv City Clinical Oncology Center · +15 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
917
total citations
- FWCI
- 49.07
- Percentile
- 100%
- References
- 26
Citations per year
Authors
19Topics & keywords
Topics
Keywords
- Medicine
- Bortezomib
- Multiple myeloma
- Population
- Subcutaneous injection
- Internal medicine
- Surgery
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.